17 results for "Meta-analysis: What did research on Ketamine find in January 2026?"

Repeated 7-day exposure to ketamine induces anxiety-like behaviors and neuronal apoptosis in mice via DRD1-medicated inhibition of Akt/Gsk-3β phosphorylation.

Cell Biology and Toxicology January 30, 2026 Jia-Yi Wei, Peng Lv, Jiayu Zhang et al.

Repeated exposure to ketamine leads to mental behavioral disorders and cognitive deficits in mice. As a neurotransmitter receptor, dopamine receptor 1 (DRD1) is involved in mental regulation and memory formation. However, the role of DRD1 in ketamine's behavioral disorder and neurotoxicity remains unclear. We found that seven-day ketamine exposure induced anxiety-like, depressive-like behavior...

DOI: 10.1007/s10565-026-10149-4 Full text Anxiety-like behavior Apoptosis Drd1 Ketamine abuse

α-tocopherol alleviates ketamine toxicity in rat brain neurons.

BMC pharmacology & toxicology January 30, 2026 Enayatollah Seydi, Sana Ghanizadeh, Farzaneh Jokar et al.

Ketamine exhibits various pharmacological effects due to its high efficacy, but reports also indicate its potential to cause brain side effects and neurotoxicity. It can induce oxidative stress and impair mitochondrial function, although the exact mechanism of its neurotoxicity remains unclear. In this study, we examined the effects of α-tocopherol on ketamine-induced toxicity in rat brain...

DOI: 10.1186/s40360-026-01083-6 Full text Ketamine Cytotoxicity Lysosome Mitochondria +3

Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study.

Journal of Affective Disorders January 30, 2026 Yao-Zu Li, Cai-Qun Zhao, Mu-Yan Zuo et al.

To evaluate the efficacy and safety of a multimodal rapid anti-depression therapy that combines esketamine treatment with dexmedetomidine patient-controlled sleep (PCSL) in patients with treatment-resistant depression (TRD). We retrospectively included 233 patients with TRD who received the multimodal treatment. Baseline clinical characteristics were collected. Follow-up assessments were...

DOI: 10.1016/j.jad.2026.121311 Full text Esketamine Treatment-resistant depression Dexmedetomidine Multimodal rapid anti-depression +1

Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.

European journal of anaesthesiology January 29, 2026 Tiantian Chu, Xiaoling Peng, Keliang Wan et al. 2 citations

Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae. This trial sought to evaluate whether prophylactic administration of esketamine during the perinatal period could prevent PPD in primiparae without predisposition to prenatal depression. A prospective, double-blind, multicentre, randomised controlled trial. Three academic hospitals. Primiparae...

DOI: 10.1097/EJA.0000000000002348 Full text

Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series.

The Journal of ECT January 29, 2026 Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón et al. 1 citation

This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning...

DOI: 10.1097/yct.0000000000001233 Full text Esketamine Treatment-resistant depression Case series Combination therapy +2

Ketamine in the treatment of bipolar depression

Brazilian Journal of Health Review January 28, 2026 Juliana Chies Galvan, Marina Chies Galvan, Rafael Moreno Ferro de Araújo

Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using...

DOI: 10.34119/bjhrv9n1-120

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Atypical Manifestation of Postoperative Delirium After an Opioid-free Prostatectomy: A Case Study Report.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses January 28, 2026 Karina Bridges, Ionela Morosanu, Lilian Njoki et al.

At a clinical research hospital, the Department of Perioperative Services has recently implemented an opioid-free anesthesia protocol for selected patients undergoing robotic-assisted prostatectomy. This protocol incorporates intraoperative infusions of ketamine, lidocaine, and magnesium as part of a multimodal analgesic strategy. The present case report describes an unusual occurrence of...

DOI: 10.1016/j.jopan.2025.11.008 Full text Ketamine Case reports Opioid-free anesthesia Patient safety +2

Brief report: Ketamine-assisted "bridge therapy" for opioid tapering in complex cases.

The American Journal on Addictions January 28, 2026 Mariana C De Oliveira, Cláudia C De Araujo Palmeira, André B Negrão et al. 1 citation

Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25-year-old woman with OUD, chronic pain, and major depressive disorder underwent an 8-week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Methadone dosage was reduced by 50%, with improved pain and craving control,...

DOI: 10.1111/ajad.70131 Full text

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

Serial ketamine infusions not effective as adjunctive care for depression

The Brown University Psychopharmacology Update January 24, 2026

Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatient treatment for depression, a randomized trial has found. Patients receiving ketamine also showed no improvement relative to those receiving midazolam on measures of cognition and quality of life. Study results were published online Oct. 22, 2025 in...

DOI: 10.1002/pu.31401 Ketamine Depression economics Placebo Midazolam +6

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

DOI: 10.1016/j.jad.2026.121230 Full text Anxiety Treatment-resistant depression Iv ketamine Real-world evidence +1

Ketamine-assisted group psychotherapy integrating cognitive processing therapy to address identity-based trauma: a pilot study

Frontiers in Psychiatry January 22, 2026 Jae Sevelius, Rachel Lynn Golden, B. Stott et al. 1 citation

Introduction Transgender and gender-expansive people experience high rates of depression, anxiety, and trauma-related distress, yet few evidence-based interventions are tailored to their needs. Kindred is a novel, group-based ketamine-assisted psychotherapy (KAP) program that integrates cognitive processing therapy (CPT) to address identity-based trauma. Methods This mixed-methods pilot study...

DOI: 10.3389/fpsyt.2025.1727487 Cognition Intervention counseling Group psychotherapy Cognitive processing therapy +7

Progress, potential and pitfalls of ketamine as a treatment for depression

Expert Opinion on Pharmacotherapy January 22, 2026 Diana Orsini, Sara Di Luch, Gabrielle F. M. Lovell et al.

Evidence supporting the use of intravenous ketamine and intranasal esketamine for depression has dramatically increased with a large number of clinical trials and real-world effectiveness studies supporting antidepressant effects. Larger studies have provided reassuring data supporting an adequate safety profile, including safety data with long-term treatment. Alternative routes of...

DOI: 10.1080/14656566.2026.2637587 Ketamine Treatment-resistant depression Antidepressant Clinical trial +4

A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial.

Pharmacological reports : PR January 22, 2026 Taichi Goto, Joy D Kreskow, Alexander L R Ross et al.

Fatigue, a prevalent symptom of chronic illness, impacts quality of life. This proof-of-concept, randomized, double-blind, crossover trial assessed the anti-fatigue effects of ketamine (0.5 mg/kg) versus midazolam (0.045 mg/kg), the active comparator. Ten participants, who were cancer survivors, with fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome, or systemic lupus...

DOI: 10.1007/s43440-025-00808-4 Full text Active placebo Chronic illness Glutamate receptor Midazolam +1

Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.

Indian Journal of Psychological Medicine January 22, 2026 Zaid Ahmad Wani, Rajnish Raj, Shabir Ahmad Dar et al.

Depression is a significant global health issue, often accompanied by suicidality, which requires urgent and effective interventions. Oral ketamine is emerging as a potential rapid-acting treatment, but data on its efficacy and tolerability remain limited, particularly in the Indian context. Thus, this retrospective study was conducted to assess the response to oral ketamine in patients with...

DOI: 10.1177/02537176251415001 Full text Depression Oral ketamine Rapid-acting antidepressant Sociocultural factors +1